The Cystic Fibrosis Foundation announced a major leadership change today.
Preston Campbell, M.D., will be stepping down from his position as president and CEO of the Cystic Fibrosis Foundation at the end of 2019.
The foundation has appointed Michael Boyle, M.D., to succeed Campbell as president and CEO. Currently, Boyle is Senior Vice President of Therapeutics Development at the foundation.
Boyle will assume his new role on January 1, 2020.
Catherine “Cam” McLoud, chair of the CF Foundation Board of Trustees, praised Campbell for his leadership of the foundation. During his tenure, Campbell expanded the foundation’s medical program and invested in research for treatment and a cure for CF, McLoud said.
“On half of the Board, we are grateful for Preston’s many enduring contributions to the CF community,” McLoud said in a statement. “His outstanding leadership, kind presence, and extraordinary commitment have strengthened who we are and shaped the progress our community has achieved.”
According to McLoud, Boyle will help “accelerate our innovative programs and advance our mission” as the foundation’s new CEO. McLoud referenced Boyle’s past leadership accomplishments, such as founding the adult CF care center at Johns Hopkins University in 1999 and helping to develop the CF Foundation’s clinical research strategy.
“He brings a combination of excellence in leadership and a strong commitment to people with CF that has been at the center of his life in medicine. The Board is proud to welcome him to his new role beginning January 1, 2020,” she said.